Eli Lilly and Company (NYSE:LLY) Shares Climb 1.3% – Here’s Why

Eli Lilly and Company (NYSE:LLY) shot up 1.3% on Tuesday. The stock traded as high as $1,177.06 and last traded at $1,157.6060. Approximately 2,121,006 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 2,977,780 shares. The stock had previously closed at $1,143.12.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst price target: Cantor Fitzgerald raised its target for Eli Lilly from $1,410 to $1,440 and maintained an “overweight” rating, implying substantial upside based on expectations for continued earnings and pipeline growth.
• Positive Sentiment: Obesity pipeline remains a major catalyst: Analysts point to retatrutide, Lilly’s next-generation triple-hormone weight-loss candidate, as a potential successor to Mounjaro and Zepbound. Its reported clinical weight-loss results and potential applications in related conditions could expand Lilly’s long-term addressable market. Eli Lilly’s Obesity Business Could Become a Much Bigger Healthcare Platform
• Positive Sentiment: Pipeline diversification continues: Lilly is testing eloralintide in an obesity-related study involving hormonal contraception and has initiated an early-stage Alzheimer’s trial. These studies are preliminary, but they reinforce the company’s efforts to build growth beyond its current GLP-1 franchise. Eli Lilly Tests Obesity Drug Eloralintide With Birth Control
• Positive Sentiment: Oncology and technical support: Jaypirca, Inluriyo and Retevmo could help offset slowing Verzenio sales, while a move above the 50-day moving average is viewed by some technical analysts as a short-term bullish signal.
• Neutral Sentiment: Investor sentiment remains constructive: Commentary highlights Lilly’s “growth flywheel” from GLP-1 demand, manufacturing expansion, new indications and earnings growth. However, these are largely forward-looking investment opinions rather than new financial results.
• Negative Sentiment: Valuation and competition remain concerns: Lilly trades at a premium multiple, leaving the stock vulnerable to profit-taking if obesity-drug growth slows, pricing pressure increases or Novo Nordisk and other competitors gain share. LLY Stock Down 2% in 3 Months
• Negative Sentiment: New obesity guidelines could create uncertainty: The World Health Organization’s childhood-obesity recommendations may increase scrutiny of how weight-loss medicines are used in younger populations, potentially affecting future market expectations for Lilly and Novo Nordisk.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LLY. HSBC upped their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. Leerink Partners raised their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 23rd. Morgan Stanley boosted their price target on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Wells Fargo & Company raised their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock’s 50 day moving average is $1,173.51 and its two-hundred day moving average is $1,094.59. The firm has a market cap of $1.09 trillion, a P/E ratio of 38.87, a PEG ratio of 1.42 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 36.66 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $25,000. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $30,000. Maseco LLP grew its position in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after buying an additional 28 shares during the period. Aventus Investment Advisors Inc. increased its stake in shares of Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after purchasing an additional 27 shares during the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. grew its holdings in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after purchasing an additional 15 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.